InsidersTradesSigma
한미약품 Stock: price and management transactions · South Korea · DART (FSS)
Follow the 한미약품 share price and the full management transaction log of the company, a listed equity based in South Korea. Shares are quoted on KR KR, under the oversight of DART (FSS). Operating in the Health Care sector, 한미약품 has recorded 117 public disclosures. Market capitalisation: €5,332bn. The latest transaction was reported on 2 July 2026 (Other). Among the most active insiders: 국민연금공단. All data is accessible without an account.
117
Insider Decl.
0
Thresholds
·
11 ops.
Buy Volume
·
16 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate 한미약품 Buy (bullish), based on 13 analysts. Average price target: ₩624,615.
17Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 9,621 of 26,213 companies
58.3
score / 100
Value45
Quality72
FCF yld1.9%
Earn yld3.4%
EV/EBITDA16.6x
ROE14%
Gross mgn57%
Net mgn11%
Debt/EBITDA1.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 2 July 2026
Declarations117 total
25 of 117 declarations
About 한미약품
Hanmi Pharmaceutical is a South Korean pharmaceutical company focused on the research and development of innovative drugs. It is listed on the XKRX.